Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Immuneering CorpIMRX · Entity 5884 | Director | June 13, 2025 | June 16, 2025 |
| LOEWS CORPL · Entity 3231 | Director | March 31, 2026 | March 31, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Immuneering Corp
Report date June 13, 2025 · Filed June 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.90 · Expires 2035-06-13 | Direct | 33,350 |
Reported balance
After 2025-06-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-13 · Grant · Acquired 33,350 · Balance 33,350 F1: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 13, 2025, and will be fully vested and exercisable on June 13, 2026, or the date of the 2026 annual meeting of stockholders, whichever comes first. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 13, 2025, and will be fully vested and exercisable on June 13, 2026, or the date of the 2026 annual meeting of stockholders, whichever comes first.
LOEWS CORP
Report date March 31, 2026 · Filed March 31, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,233 |
Reported balance
After 2026-03-31 transaction · row 1
1 source rowRow 1 · 2026-03-31 · Grant · Acquired 235 · Balance 5,233 F1: Represents quarterly grant of common stock in respect of director compensation under the Loews Corporation 2025 Incentive Compensation Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents quarterly grant of common stock in respect of director compensation under the Loews Corporation 2025 Incentive Compensation Plan.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CANTEL MEDICAL CORP
Report date June 02, 2021 · Filed June 02, 2021
Section 16 reporting ended · disclosed 2021-06-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $.10 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-06-02 transaction · row 1
1 source rowRow 1 · 2021-06-02 · Disposition to issuer · Disposed 4,159 · Balance 0 F1: Represents shares that, at the effective time of the First Merger (as defined in the Agreement and Plan of Merger, as amended and restated on March 1, 2021 (the "Merger Agreement"), by and among Cantel Medical Corp., a Delaware corporation (the "Company"), STERIS plc, an Irish public limited company ("STERIS"), Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC) (the "Effective Time"), were converted into the right to receive (i) 0.33787 ordinary shares, par value $0.001 per share, of STERIS (the "Stock Consideration"), and (ii) $16.93 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration"). F2: Based on the closing price of ordinary shares of STERIS on June 1, 2021, the last trading day before the Effective Time, the value of the Stock Consideration payable per share of common stock, par value $.10 per share, of the Company ("Company Common Stock") was $63.66, and the value of the Merger Consideration payable per share of Company Common Stock pursuant to the Merger Agreement was $80.59. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares that, at the effective time of the First Merger (as defined in the Agreement and Plan of Merger, as amended and restated on March 1, 2021 (the "Merger Agreement"), by and among Cantel Medical Corp., a Delaware corporation (the "Company"), STERIS plc, an Irish public limited company ("STERIS"), Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC) (the "Effective Time"), were converted into the right to receive (i) 0.33787 ordinary shares, par value $0.001 per share, of STERIS (the "Stock Consideration"), and (ii) $16.93 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration").
F2: Based on the closing price of ordinary shares of STERIS on June 1, 2021, the last trading day before the Effective Time, the value of the Stock Consideration payable per share of common stock, par value $.10 per share, of the Company ("Company Common Stock") was $63.66, and the value of the Merger Consideration payable per share of Company Common Stock pursuant to the Merger Agreement was $80.59.
Mirror Merger Sub 2, LLC
Report date March 01, 2021 · Filed March 03, 2021
Section 16 reporting ended · disclosed 2021-03-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-03-01 · Disposition to issuer · Disposed 2,477 · Balance 0 F1: Each Deferred Stock Unit is the economic equivalent of one share of non-voting common stock. F2: This Deferred Stock Unit award, which was granted on November 2, 2020, was canceled and converted in the March 1, 2021 merger of the Issuer and Morgan Stanley (the Merger) into the right to receive a cash payment of $73 per share for a total of $180,821.00. |
| Deferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2021-11-01 | Direct | 0 |
Reported balance
After 2021-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-03-01 · Disposition to issuer · Disposed 3,363 · Balance 0 F1: Each Deferred Stock Unit is the economic equivalent of one share of non-voting common stock. F3: This Deferred Stock Unit award, which was granted on November 1, 2019, was canceled and converted in the Merger into the right to receive a cash payment of $73 per share for a total of $245,499.00. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.90 · Expires 2023-11-01 | Direct | 0 |
Reported balance
After 2021-03-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-03-01 · Disposition to issuer · Disposed 4,045 · Balance 0 F4: This option award, which was granted on November 1, 2013, was canceled and converted in the Merger into the right to receive a cash payment of $73 per share for a total of $125,799.50. |
| Phantom StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-03-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-03-01 · Disposition to issuer · Disposed 3,252 · Balance 0 F5: Each Phantom Stock Unit is the economic equivalent of one share of non-voting common stock. F6: This Phantom Stock Unit award, which was granted on November 1, 2017, was canceled and converted in the Merger into the right to receive a cash payment of $73 per share for a total of $237,396.00. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Deferred Stock Unit is the economic equivalent of one share of non-voting common stock.
F2: This Deferred Stock Unit award, which was granted on November 2, 2020, was canceled and converted in the March 1, 2021 merger of the Issuer and Morgan Stanley (the Merger) into the right to receive a cash payment of $73 per share for a total of $180,821.00.
F3: This Deferred Stock Unit award, which was granted on November 1, 2019, was canceled and converted in the Merger into the right to receive a cash payment of $73 per share for a total of $245,499.00.
F4: This option award, which was granted on November 1, 2013, was canceled and converted in the Merger into the right to receive a cash payment of $73 per share for a total of $125,799.50.
F5: Each Phantom Stock Unit is the economic equivalent of one share of non-voting common stock.
F6: This Phantom Stock Unit award, which was granted on November 1, 2017, was canceled and converted in the Merger into the right to receive a cash payment of $73 per share for a total of $237,396.00.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 01, 2023 Filed Dec 4, 2023 21:16 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionCommon Stock | 2,250 | $47.84 | $107,640.00 |
DisclosureSEC source: 0000060086-23-000199 · wk-form4_1701724572.xml · nonDerivative · entry 1 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,542 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 11, 2022. Read SEC document |
| September 01, 2023 Filed Sep 5, 2023 20:06 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionStock Appreciation Right · Derivative | 2,250 | $0.00 Strike: $46.99 | $0.00 |
DisclosureSEC source: 0000060086-23-000159 · wk-form4_1693944358.xml · derivative · entry 4 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,250 shares Expires 2023-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 11, 2022. F3 · price: The Reporting Person received the Derivative Security pursuant to a stock appreciation right grant at no cost. Read SEC document |
| September 01, 2023 Filed Sep 5, 2023 20:06 UTC | LOEWS CORP L · Entity 3231 | SaleCommon Stock | 561 | $62.56 | $35,096.16 |
DisclosureSEC source: 0000060086-23-000159 · wk-form4_1693944358.xml · nonDerivative · entry 3 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,292 F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 11, 2022. F2 · price: Represents the weighted average price of multiple transactions with a range of prices between $62.46 and $62.67. The Reporting Person, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, undertakes to provide further information regarding the number of securities at each separate price sold. Read SEC document |
| September 01, 2023 Filed Sep 5, 2023 20:06 UTC | LOEWS CORP L · Entity 3231 | Disposition to issuerCommon Stock | 1,689 | $62.58 | $105,697.62 |
DisclosureSEC source: 0000060086-23-000159 · wk-form4_1693944358.xml · nonDerivative · entry 2 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,853 F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 11, 2022. Read SEC document |
| September 01, 2023 Filed Sep 5, 2023 20:06 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionCommon Stock | 2,250 | $46.99 | $105,727.50 |
DisclosureSEC source: 0000060086-23-000159 · wk-form4_1693944358.xml · nonDerivative · entry 1 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,542 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 11, 2022. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 16:25 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 17,500 | $0.00 Strike: $9.32 | $0.00 |
DisclosureSEC source: 0001790340-23-000031 · wk-form4_1686860705.xml · derivative · entry 1 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Class A Common Stock · 17,500 shares Expires 2033-06-14 F1 · derivative.exercise_date: The option vests and becomes exercisable in substantially equal monthly installments over a one-year period with a vesting commencement date of June 14, 2023, and will be fully vested and exercisable on June 14, 2024, or the date of the 2024 annual meeting of stockholders, whichever comes first. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 20:48 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionStock Appreciation Right · Derivative | 2,250 | $0.00 Strike: $44.44 | $0.00 |
DisclosureSEC source: 0000060086-23-000122 · wk-form4_1685738908.xml · derivative · entry 4 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,250 shares Expires 2023-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 11, 2022. F3 · price: The Reporting Person received the Derivative Security pursuant to a stock appreciation right grant at no cost. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 20:48 UTC | LOEWS CORP L · Entity 3231 | SaleCommon Stock | 474 | $56.30 | $26,686.20 |
DisclosureSEC source: 0000060086-23-000122 · wk-form4_1685738908.xml · nonDerivative · entry 3 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,292 F1 · kind: The transactions reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 11, 2022. F2 · price: Represents the weighted average price of multiple transactions with a range of prices between $56.19 and $56.41. The Reporting Person, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, undertakes to provide further information regarding the number of securities at each separate price sold. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 20:48 UTC | LOEWS CORP L · Entity 3231 | Disposition to issuerCommon Stock | 1,776 | $56.28 | $99,953.28 |
DisclosureSEC source: 0000060086-23-000122 · wk-form4_1685738908.xml · nonDerivative · entry 2 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,766 F1 · kind: The transactions reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 11, 2022. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 20:48 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionCommon Stock | 2,250 | $44.44 | $99,990.00 |
DisclosureSEC source: 0000060086-23-000122 · wk-form4_1685738908.xml · nonDerivative · entry 1 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,542 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 11, 2022. Read SEC document |
| May 10, 2023 Filed May 10, 2023 19:47 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionRestricted Stock Units · Derivative | 1,567 | $0.00 | $0.00 |
DisclosureSEC source: 0000060086-23-000105 · wf-form4_168374802648879.xml · derivative · entry 3 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,567 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: As previously reported on Table II of a Form 4 filed in connection therewith, on May 10, 2022, the Reporting Person was granted 1,567 RSUs, which vested on the first anniversary of the grant date. The common stock into which such vested RSUs converted is reported on Table I of this Form 4. F4 · derivative.expiration_date: As previously reported on Table II of a Form 4 filed in connection therewith, on May 10, 2022, the Reporting Person was granted 1,567 RSUs, which vested on the first anniversary of the grant date. The common stock into which such vested RSUs converted is reported on Table I of this Form 4. Read SEC document |
| May 10, 2023 Filed May 10, 2023 19:47 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionCommon Stock | 1,567 | $0.00 | $0.00 |
DisclosureSEC source: 0000060086-23-000105 · wf-form4_168374802648879.xml · nonDerivative · entry 1 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,292 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · acquired: Represents the conversion into common stock upon vesting of previously awarded restricted stock units ("RSUs"). Read SEC document |
| May 09, 2023 Filed May 10, 2023 19:47 UTC | LOEWS CORP L · Entity 3231 | GrantRestricted Stock Units · Derivative | 1,706 | $0.00 | $0.00 |
DisclosureSEC source: 0000060086-23-000105 · wf-form4_168374802648879.xml · derivative · entry 2 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,706 Underlying: Common Stock · 1,706 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs vest on May 9, 2024. Shares of the Issuer's common stock will be delivered to the Reporting Person upon vesting, subject to any election to defer delivery of shares made by the Reporting Person. F3 · derivative.expiration_date: The RSUs vest on May 9, 2024. Shares of the Issuer's common stock will be delivered to the Reporting Person upon vesting, subject to any election to defer delivery of shares made by the Reporting Person. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 17:50 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionStock Appreciation Right · Derivative | 2,250 | $0.00 Strike: $43.89 | $0.00 |
DisclosureSEC source: 0000060086-23-000075 · wf-form4_167777944574391.xml · derivative · entry 4 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,250 shares Expires 2023-03-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The Reporting Person received the Derivative Security pursuant to a stock appreciation right grant at no cost. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 17:50 UTC | LOEWS CORP L · Entity 3231 | SaleCommon Stock | 625 | $60.98 | $38,112.50 |
DisclosureSEC source: 0000060086-23-000075 · wf-form4_167777944574391.xml · nonDerivative · entry 3 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,725 F1 · price: Represents the weighted average price of multiple transactions with a range of prices between $60.75 and $60.99. The Reporting Person, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, undertakes to provide further information regarding the number of securities at each separate price sold. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 17:50 UTC | LOEWS CORP L · Entity 3231 | Disposition to issuerCommon Stock | 1,625 | $60.75 | $98,718.75 |
DisclosureSEC source: 0000060086-23-000075 · wf-form4_167777944574391.xml · nonDerivative · entry 2 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,350 Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 17:50 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionCommon Stock | 2,250 | $43.89 | $98,752.50 |
DisclosureSEC source: 0000060086-23-000075 · wf-form4_167777944574391.xml · nonDerivative · entry 1 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 18:33 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionStock Appreciation Right · Derivative | 2,250 | $0.00 Strike: $40.47 | $0.00 |
DisclosureSEC source: 0000060086-22-000128 · wf-form4_167000601029174.xml · derivative · entry 4 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,250 shares Expires 2022-12-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The Reporting Person received the Derivative Security pursuant to a stock appreciation right grant at no cost. Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 18:33 UTC | LOEWS CORP L · Entity 3231 | SaleCommon Stock | 698 | $57.90 | $40,414.20 |
DisclosureSEC source: 0000060086-22-000128 · wf-form4_167000601029174.xml · nonDerivative · entry 3 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,725 F1 · price: Represents the weighted average price of multiple transactions with a range of prices between $57.82 and $58.66. The Reporting Person, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, undertakes to provide further information regarding the number of securities at each separate price sold. Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 18:33 UTC | LOEWS CORP L · Entity 3231 | Disposition to issuerCommon Stock | 1,552 | $58.66 | $91,040.32 |
DisclosureSEC source: 0000060086-22-000128 · wf-form4_167000601029174.xml · nonDerivative · entry 2 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,423 Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 18:33 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionCommon Stock | 2,250 | $40.47 | $91,057.50 |
DisclosureSEC source: 0000060086-22-000128 · wf-form4_167000601029174.xml · nonDerivative · entry 1 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 15:40 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionStock Appreciation Right · Derivative | 2,250 | $0.00 Strike: $41.14 | $0.00 |
DisclosureSEC source: 0000060086-22-000086 · wf-form4_166247879429976.xml · derivative · entry 4 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,250 shares Expires 2022-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The Reporting Person received the Derivative Security pursuant to a stock appreciation right grant at no cost. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 15:40 UTC | LOEWS CORP L · Entity 3231 | SaleCommon Stock | 572 | $54.90 | $31,402.80 |
DisclosureSEC source: 0000060086-22-000086 · wf-form4_166247879429976.xml · nonDerivative · entry 3 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,725 F1 · price: Represents the weighted average price of multiple transactions with a range of prices between $54.90 and $55.16. The Reporting Person, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, undertakes to provide further information regarding the number of securities at each separate price sold. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 15:40 UTC | LOEWS CORP L · Entity 3231 | Disposition to issuerCommon Stock | 1,678 | $55.16 | $92,558.48 |
DisclosureSEC source: 0000060086-22-000086 · wf-form4_166247879429976.xml · nonDerivative · entry 2 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,297 Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 15:40 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionCommon Stock | 2,250 | $41.14 | $92,565.00 |
DisclosureSEC source: 0000060086-22-000086 · wf-form4_166247879429976.xml · nonDerivative · entry 1 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 21, 2022 Filed Jun 23, 2022 17:08 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 14,200 | $0.00 Strike: $4.63 | $0.00 |
DisclosureSEC source: 0001415889-22-006900 · form4-06232022_020628.xml · derivative · entry 1 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,200 Underlying: Class A Common Stock · 14,200 shares Expires 2032-06-20 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 21, 2022, and will be fully vested and exercisable on June 21, 2023, or the date of the 2023 annual meeting of stockholders, whichever is earlier. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 17:42 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionStock Appreciation Right · Derivative | 2,250 | $0.00 Strike: $39.80 | $0.00 |
DisclosureSEC source: 0000060086-22-000060 · wf-form4_165419176435714.xml · derivative · entry 4 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,250 shares Expires 2022-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The Reporting Person received the Derivative Security pursuant to a stock appreciation right grant at no cost. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 17:42 UTC | LOEWS CORP L · Entity 3231 | SaleCommon Stock | 883 | $64.55 | $56,997.65 |
DisclosureSEC source: 0000060086-22-000060 · wf-form4_165419176435714.xml · nonDerivative · entry 3 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,725 F1 · price: Represents the weighted average price of multiple transactions with a range of prices between $64.54 and $65.48. The Reporting Person, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, undertakes to provide further information regarding the number of securities at each separate price sold. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 17:42 UTC | LOEWS CORP L · Entity 3231 | Disposition to issuerCommon Stock | 1,367 | $65.48 | $89,511.16 |
DisclosureSEC source: 0000060086-22-000060 · wf-form4_165419176435714.xml · nonDerivative · entry 2 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,608 Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 17:42 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionCommon Stock | 2,250 | $39.80 | $89,550.00 |
DisclosureSEC source: 0000060086-22-000060 · wf-form4_165419176435714.xml · nonDerivative · entry 1 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2022 Filed May 11, 2022 19:48 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionRestricted Stock Units · Derivative | 1,725 | $0.00 | $0.00 |
DisclosureSEC source: 0000060086-22-000034 · wf-form4_165229846679250.xml · derivative · entry 3 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,725 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: As previously reported on Table II of a Form 4 filed in connection therewith, on May 11, 2021, the Reporting Person was granted 1,725 RSUs, which vested on the first anniversary of the grant date. The common stock into which such vested RSUs converted is reported on Table I of this Form 4. F4 · derivative.expiration_date: As previously reported on Table II of a Form 4 filed in connection therewith, on May 11, 2021, the Reporting Person was granted 1,725 RSUs, which vested on the first anniversary of the grant date. The common stock into which such vested RSUs converted is reported on Table I of this Form 4. Read SEC document |
| May 11, 2022 Filed May 11, 2022 19:48 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionCommon Stock | 1,725 | $0.00 | $0.00 |
DisclosureSEC source: 0000060086-22-000034 · wf-form4_165229846679250.xml · nonDerivative · entry 1 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,725 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · acquired: Represents the conversion into common stock upon vesting of previously awarded restricted stock units ("RSUs"). Read SEC document |
| May 10, 2022 Filed May 11, 2022 19:48 UTC | LOEWS CORP L · Entity 3231 | GrantRestricted Stock Units · Derivative | 1,567 | $0.00 | $0.00 |
DisclosureSEC source: 0000060086-22-000034 · wf-form4_165229846679250.xml · derivative · entry 2 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,567 Underlying: Common Stock · 1,567 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs vest on May 10, 2023. Shares of the Issuer's common stock will be delivered to the Reporting Person upon vesting, subject to any election to defer delivery of shares made by the Reporting Person. F3 · derivative.expiration_date: The RSUs vest on May 10, 2023. Shares of the Issuer's common stock will be delivered to the Reporting Person upon vesting, subject to any election to defer delivery of shares made by the Reporting Person. Read SEC document |
| March 15, 2022 Filed Mar 15, 2022 17:53 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 6,000 | $6.40 | $38,400.00 |
DisclosureSEC source: 0001415889-22-002974 · form4-03152022_020312.xml · nonDerivative · entry 1 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,500 F1 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $6.35 to $6.45. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares acquired at each price. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 20:48 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionStock Appreciation Right · Derivative | 2,250 | $0.00 Strike: $39.41 | $0.00 |
DisclosureSEC source: 0001567619-22-006057 · doc1.xml · derivative · entry 4 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,250 shares Expires 2022-03-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The Reporting Person received the Derivative Security pursuant to a stock appreciation right grant at no cost. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 20:48 UTC | LOEWS CORP L · Entity 3231 | SaleCommon Stock | 797 | $59.89 | $47,732.33 |
DisclosureSEC source: 0001567619-22-006057 · doc1.xml · nonDerivative · entry 3 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Represents the weighted average price of multiple transactions with a range of prices between $59.87 and $61.02. The Reporting Person, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, undertakes to provide further information regarding the number of securities at each separate price sold. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 20:48 UTC | LOEWS CORP L · Entity 3231 | Disposition to issuerCommon Stock | 1,453 | $61.02 | $88,662.06 |
DisclosureSEC source: 0001567619-22-006057 · doc1.xml · nonDerivative · entry 2 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 797 Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 20:48 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionCommon Stock | 2,250 | $39.41 | $88,672.50 |
DisclosureSEC source: 0001567619-22-006057 · doc1.xml · nonDerivative · entry 1 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2021 Filed Dec 2, 2021 17:57 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionStock Appreciation Right · Derivative | 1,500 | $0.00 Strike: $37.78 | $0.00 |
DisclosureSEC source: 0001567619-21-021429 · doc1.xml · derivative · entry 4 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires 2021-12-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The Reporting Person received the Derivative Security pursuant to a stock appreciation right grant at no cost. Read SEC document |
| December 01, 2021 Filed Dec 2, 2021 17:57 UTC | LOEWS CORP L · Entity 3231 | SaleCommon Stock | 459 | $54.71 | $25,111.89 |
DisclosureSEC source: 0001567619-21-021429 · doc1.xml · nonDerivative · entry 3 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Represents the weighted average price of multiple transactions with a range of prices between $54.43 and $54.71. The Reporting Person, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, undertakes to provide further information regarding the number of securities at each separate price sold. Read SEC document |
| December 01, 2021 Filed Dec 2, 2021 17:57 UTC | LOEWS CORP L · Entity 3231 | Disposition to issuerCommon Stock | 1,041 | $54.43 | $56,661.63 |
DisclosureSEC source: 0001567619-21-021429 · doc1.xml · nonDerivative · entry 2 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 459 Read SEC document |
| December 01, 2021 Filed Dec 2, 2021 17:57 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionCommon Stock | 1,500 | $37.78 | $56,670.00 |
DisclosureSEC source: 0001567619-21-021429 · doc1.xml · nonDerivative · entry 1 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2021 Filed Sep 1, 2021 20:41 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionStock Appreciation Right · Derivative | 1,500 | $0.00 Strike: $35.04 | $0.00 |
DisclosureSEC source: 0001567619-21-016571 · doc1.xml · derivative · entry 4 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires 2021-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The Reporting Person received the Derivative Security pursuant to a stock appreciation right grant at no cost. Read SEC document |
| September 01, 2021 Filed Sep 1, 2021 20:41 UTC | LOEWS CORP L · Entity 3231 | SaleCommon Stock | 561 | $55.62 | $31,202.82 |
DisclosureSEC source: 0001567619-21-016571 · doc1.xml · nonDerivative · entry 3 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Represents the weighted average price of multiple transactions with a range of prices between $55.61 and $55.97. The Reporting Person, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, undertakes to provide further information regarding the number of securities at each separate price sold. Read SEC document |
| September 01, 2021 Filed Sep 1, 2021 20:41 UTC | LOEWS CORP L · Entity 3231 | Disposition to issuerCommon Stock | 939 | $55.97 | $52,555.83 |
DisclosureSEC source: 0001567619-21-016571 · doc1.xml · nonDerivative · entry 2 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 561 Read SEC document |
| September 01, 2021 Filed Sep 1, 2021 20:41 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionCommon Stock | 1,500 | $35.04 | $52,560.00 |
DisclosureSEC source: 0001567619-21-016571 · doc1.xml · nonDerivative · entry 1 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 06:04 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 3,500 | $15.00 | $52,500.00 |
DisclosureSEC source: 0001104659-21-099726 · tm2123807-3_4seq1.xml · nonDerivative · entry 1 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Read SEC document |
| July 29, 2021 Filed Jul 30, 2021 16:27 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 28,371 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001104659-21-098274 · tm2123556d10_4seq1.xml · derivative · entry 1 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,371 Underlying: Class A Common Stock · 28,371 shares Expires 2031-07-28 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on July 29, 2022 and then in equal monthly installments over the subsequent three years, subject to Ms. Berman's continued service as a non-employee member of the Issuer's board of directors through each applicable vesting date. Read SEC document |
| June 02, 2021 Filed Jun 2, 2021 17:21 UTC | CANTEL MEDICAL CORP CMD · Entity 138805 | Disposition to issuerCommon Stock, par value $.10 per share | 4,159 | $80.59 | $335,173.81 |
DisclosureSEC source: 0001104659-21-075840 · tm2118222-2_4seq1.xml · nonDerivative · entry 1 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Represents shares that, at the effective time of the First Merger (as defined in the Agreement and Plan of Merger, as amended and restated on March 1, 2021 (the "Merger Agreement"), by and among Cantel Medical Corp., a Delaware corporation (the "Company"), STERIS plc, an Irish public limited company ("STERIS"), Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC) (the "Effective Time"), were converted into the right to receive (i) 0.33787 ordinary shares, par value $0.001 per share, of STERIS (the "Stock Consideration"), and (ii) $16.93 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration"). F2 · kind: Based on the closing price of ordinary shares of STERIS on June 1, 2021, the last trading day before the Effective Time, the value of the Stock Consideration payable per share of common stock, par value $.10 per share, of the Company ("Company Common Stock") was $63.66, and the value of the Merger Consideration payable per share of Company Common Stock pursuant to the Merger Agreement was $80.59. F1 · shares: Represents shares that, at the effective time of the First Merger (as defined in the Agreement and Plan of Merger, as amended and restated on March 1, 2021 (the "Merger Agreement"), by and among Cantel Medical Corp., a Delaware corporation (the "Company"), STERIS plc, an Irish public limited company ("STERIS"), Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC) (the "Effective Time"), were converted into the right to receive (i) 0.33787 ordinary shares, par value $0.001 per share, of STERIS (the "Stock Consideration"), and (ii) $16.93 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration"). F2 · shares: Based on the closing price of ordinary shares of STERIS on June 1, 2021, the last trading day before the Effective Time, the value of the Stock Consideration payable per share of common stock, par value $.10 per share, of the Company ("Company Common Stock") was $63.66, and the value of the Merger Consideration payable per share of Company Common Stock pursuant to the Merger Agreement was $80.59. F1 · price: Represents shares that, at the effective time of the First Merger (as defined in the Agreement and Plan of Merger, as amended and restated on March 1, 2021 (the "Merger Agreement"), by and among Cantel Medical Corp., a Delaware corporation (the "Company"), STERIS plc, an Irish public limited company ("STERIS"), Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC) (the "Effective Time"), were converted into the right to receive (i) 0.33787 ordinary shares, par value $0.001 per share, of STERIS (the "Stock Consideration"), and (ii) $16.93 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration"). F2 · price: Based on the closing price of ordinary shares of STERIS on June 1, 2021, the last trading day before the Effective Time, the value of the Stock Consideration payable per share of common stock, par value $.10 per share, of the Company ("Company Common Stock") was $63.66, and the value of the Merger Consideration payable per share of Company Common Stock pursuant to the Merger Agreement was $80.59. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 17:44 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionStock Appreciation Right · Derivative | 1,500 | $0.00 Strike: $42.02 | $0.00 |
DisclosureSEC source: 0001567619-21-011498 · doc1.xml · derivative · entry 4 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires 2021-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The Reporting Person received the Derivative Security pursuant to a stock appreciation right grant at no cost. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.